[12] Later in 2007, Devgen acquired Monsanto's subsidiaries in India, Pakistan, and the Philippines that developed and sold hybrid seeds for 4 crops: rice, sunflower, sorghum and pearl millet, for about $26M.[13] Shortly thereafter, it announced its intention to spin off its pharma division.[14] In late 2008 it fired its 19 pharma employees, leaving about 200 remaining in its ag businesses.[14] In 2010, some former Devgen pharma employees started a pharmaceutical company, Amakem NV, to develop kinase inhibitors they had discovered at Devgen.[15][16]